Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer | BMC Cancer | Full Text

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer | BMC Cancer | Full Text

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients...

Authors:Maryam Soleimani Dodaran, Simone Borgoni, Emre Sofyalı, Pernette J. Verschure, Stefan Wiemann, Perry D. Moerland and Antoine H. C. van Kampen

Citation:BMC Cancer 2020 20:676

Content type:Research article

 

Published on: 19 July 2020

• ViewFull Text
 
• ViewPDF